ArriVent’s stock plummets on Phase III NSCLC trial failure
Phase 3negativeNegative
AI Analysis
Summary
ArriVent's Phase III NSCLC trial failed, causing significant stock decline. The disappointing result comes shortly after J&J's successful trial in the same patient population.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Phase III NSCLC trial failed
Importance:8/10
Sentiment:
-0.90
Phase 3 failureNSCLCstock declineclinical trialoncology
Related Companies
Read the original article
Published by Clinical Trials Arena on October 7, 2026 1:50 PM